Fortovase is a drug owned by Hoffmann La Roche Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 16, 2020. Details of Fortovase's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6352717 (Pediatric) | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
May, 2020
(4 years ago) |
Expired
|
| US6352717 | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
Nov, 2019
(5 years ago) |
Expired
|
|
US6008228 (Pediatric) | Pharmaceutical compositions containing proteinase inhibitors |
Dec, 2015
(8 years ago) |
Expired
|
| US6008228 | Pharmaceutical compositions containing proteinase inhibitors |
Jun, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Fortovase is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fortovase's family patents as well as insights into ongoing legal events on those patents.
Fortovase's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Fortovase's generic launch date based on the expiry of its last outstanding patent is estimated to be May 16, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fortovase Generics:
There are no approved generic versions for Fortovase as of now.
About Fortovase
Fortovase is a drug owned by Hoffmann La Roche Inc. Fortovase uses Saquinavir as an active ingredient. Fortovase was launched by Hoffmann La Roche in 1997.
Approval Date:
Fortovase was approved by FDA for market use on 07 November, 1997.
Active Ingredient:
Fortovase uses Saquinavir as the active ingredient. Check out other Drugs and Companies using Saquinavir ingredient
Dosage:
Fortovase is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE | Discontinued | ORAL |